Septerna (SEPN) Cash from Financing Activities (2024 - 2026)
Septerna (SEPN) posted quarterly Cash from Financing Activities of $333000.0 for Q1 2026, up 404.55% year-over-year from $66000.0 in Q1 2025, and down 67.38% quarter-over-quarter from $1.0 million in Q4 2025.
Septerna (SEPN) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Septerna's Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $333000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 404.55% year-over-year to $333000.0; the TTM figure through Mar 2026 stood at $2.0 million (down 99.35% YoY), while the FY2025 annual figure was $1.7 million, down 99.55% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $333000.0, down from $1.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $304.2 million in Q4 2024, with the low at -$1.3 million in Q3 2024.
- The 3-year median for Cash from Financing Activities is $333000.0 (2026), against an average of $43.6 million.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 99.66% in 2025, then jumped 404.55% in 2026.
- Septerna's Cash from Financing Activities stood at $304.2 million in 2024, then slumped by 99.66% to $1.0 million in 2025, then slumped by 67.38% to $333000.0 in 2026.
- Business Quant data shows SEPN's Cash from Financing Activities at $333000.0 in Q1 2026, $1.0 million in Q4 2025, and $263000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 16.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.82 Mn |
| Jun 30, 2026 | 16.82 Mn |
| Mar 31, 2026 | 333,000.00 |
| Mar 31, 2026 | 333,000.00 |
| Dec 31, 2025 | 1.02 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 263,000.00 |
| Sep 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 339,000.00 |
| Jun 30, 2025 | 339,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Dec 31, 2024 | 304.15 Mn |
| Dec 31, 2024 | 304.15 Mn |
| Sep 30, 2024 | -1.32 Mn |
| Sep 30, 2024 | -1.32 Mn |